NCT06668324View on ClinicalTrials.gov

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Multiple Sclerosis
Trial Locations (1)

07936

Novartis Investigative site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY